Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
University of California, Irvine
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01720602CT.gov Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | — | Completed | — | — | — |
NCT01153672CT.gov Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | — | Completed | — | — | — |
NCT01084057CT.gov Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00258349CT.gov Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | — | Completed | — | — | — |
NCT00368875CT.gov Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00132002CT.gov Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Male Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | University of California, Irvine | P2 | BBB · 72 |
| Cyclophosphamide | Wake Forest University Health Sciences | P2 | BBB |
| Nivestim | University of Washington | P2 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P2 | BBB |
| Cediranib | University of Chicago | P2 | BB |
| Capecitabine | Jonsson Comprehensive Cancer Center | P2 | BB |
| Tamoxifen | Jose Pablo Leone | P3 | BB |
| Sargramostim | University of Washington | P2 | BB |
| Trastuzumab | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB |
+42 more in the Male Breast Carcinoma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Male Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/irinotecan-male-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →